Patents by Inventor Martin Shenker
Martin Shenker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340411Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: December 13, 2022Publication date: October 26, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Publication number: 20230277533Abstract: The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: February 12, 2021Publication date: September 7, 2023Inventors: Andrew Alistair WYLIE, Solomon Martin SHENKER, Pamela Jean SULLIVAN, Frank STEGMEIER, Anne Louise CADZOW, Hanlan LIU, Kerstin Wolf SINKEVICIUS
-
Publication number: 20230220380Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: December 13, 2022Publication date: July 13, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20230088186Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: August 25, 2022Publication date: March 23, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Patent number: 11608500Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: June 9, 2022Date of Patent: March 21, 2023Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20220315921Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: June 9, 2022Publication date: October 6, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Patent number: 11459544Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: March 29, 2022Date of Patent: October 4, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Publication number: 20220267727Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 29, 2022Publication date: August 25, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Patent number: 11421228Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: June 24, 2021Date of Patent: August 23, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20220220442Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 29, 2022Publication date: July 14, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Patent number: 11332713Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: November 18, 2020Date of Patent: May 17, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Publication number: 20220110974Abstract: The present disclosure provides methods and compositions related to the modification of Tregs to increase therapeutic efficacy. In some embodiments, Tregs modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance immunosuppressive functions of the immune cells are provided. In some embodiments, Tregs further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating an autoimmune diseases using the modified Tregs described herein are also provided.Type: ApplicationFiled: January 31, 2020Publication date: April 14, 2022Inventors: John CHO, Jason MERKIN, Noah Jacob TUBO, James Martin KABERNA, II, Solomon Martin SHENKER, Kerem Jonatan TUNCEL
-
Patent number: 11261428Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: March 14, 2019Date of Patent: March 1, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Publication number: 20210388349Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: June 24, 2021Publication date: December 16, 2021Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Patent number: 11111493Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: February 14, 2020Date of Patent: September 7, 2021Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo
-
Publication number: 20210071140Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: November 18, 2020Publication date: March 11, 2021Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO, James Martin KABERNA, II
-
Publication number: 20200181610Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO
-
Publication number: 20190284530Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah BENSON, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Publication number: 20190284553Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah BENSON, Jason MERKIN, Gregory V. KRYUKOV, Solomon Martin SHENKER, Michael SCHLABACH, Noah TUBO
-
Publication number: 20190284529Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 14, 2019Publication date: September 19, 2019Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo